Thermo Fisher wrapped up 2021 by buying bioscience reagents specialist PeproTech for $1.9 billion in cash, the Massachusetts-based behemoth announced last week.
The deal gives Thermo Fisher access to New Jersey-based PeproTech’s recombinant proteins portfolio, “an excellent strategic fit within our biosciences business,” per the press release.